NDATOPICALLOTION
Approved
May 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
CLEOCIN T (clindamycin phosphate) by Pfizer is mechanism of action the mechanism of action of clindamycin in treating acne vulgaris is unknown. First approved in 1989.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEOCIN T is a topical lotion formulation of clindamycin phosphate approved for acne vulgaris treatment. The exact mechanism of action in acne is unknown, though clindamycin is a lincosamide antibiotic with broad-spectrum activity. This product represents a mature, well-established topical dermatology offering from Pfizer.
LOE Approaching
Product faces significant generic pressure (30% competitive intensity) with LOE approaching, suggesting declining team headcount and shift toward defending market share against generics.
Mechanism of Action
Mechanism of Action The mechanism of action of clindamycin in treating acne vulgaris is unknown.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Started Oct 2025
200 enrolled
Acne Vulgaris
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
Started Jan 2017
22 enrolled
Actinic Keratosis
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
Started Apr 2013
1,018 enrolled
Acne Vulgaris
W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers
Started Nov 2008
64 enrolled
Acne Vulgaris
Worked on CLEOCIN T at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.